The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1


Antibody protection against flaviviruses is associated with the development of neutralizing antibodies against the viral envelope (E) protein. Prior studies with West Nile virus (WNV) identified therapeutic mouse and human monoclonal antibodies (MAbs) that recognized epitopes on domain III (DIII) of the E protein. To identify an analogous panel of neutralizing antibodies against DENV type-1 (DENV-1), we immunized mice with a genotype 2 strain of DENV-1 virus and generated 79 new MAbs, 16 of which strongly inhibited infection by the homologous virus and localized to DIII. Surprisingly, only two MAbs, DENV1-E105 and DENV1-E106, retained strong binding and neutralizing activity against all five DENV-1 genotypes. In an immunocompromised mouse model of infection, DENV1-E105 and DENV1-E106 exhibited therapeutic activity even when administered as a single dose four days after inoculation with a heterologous genotype 4 strain of DENV-1. Using epitope mapping and X-ray crystallographic analyses, we localized the neutralizing determinants for the strongly inhibitory MAbs to distinct regions on DIII. Interestingly, sequence variation in DIII alone failed to explain disparities in neutralizing potential of MAbs among different genotypes. Overall, our experiments define a complex structural epitope on DIII of DENV-1 that can be recognized by protective antibodies with therapeutic potential.


Vyšlo v časopise: The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1. PLoS Pathog 6(4): e32767. doi:10.1371/journal.ppat.1000823
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1000823

Souhrn

Antibody protection against flaviviruses is associated with the development of neutralizing antibodies against the viral envelope (E) protein. Prior studies with West Nile virus (WNV) identified therapeutic mouse and human monoclonal antibodies (MAbs) that recognized epitopes on domain III (DIII) of the E protein. To identify an analogous panel of neutralizing antibodies against DENV type-1 (DENV-1), we immunized mice with a genotype 2 strain of DENV-1 virus and generated 79 new MAbs, 16 of which strongly inhibited infection by the homologous virus and localized to DIII. Surprisingly, only two MAbs, DENV1-E105 and DENV1-E106, retained strong binding and neutralizing activity against all five DENV-1 genotypes. In an immunocompromised mouse model of infection, DENV1-E105 and DENV1-E106 exhibited therapeutic activity even when administered as a single dose four days after inoculation with a heterologous genotype 4 strain of DENV-1. Using epitope mapping and X-ray crystallographic analyses, we localized the neutralizing determinants for the strongly inhibitory MAbs to distinct regions on DIII. Interestingly, sequence variation in DIII alone failed to explain disparities in neutralizing potential of MAbs among different genotypes. Overall, our experiments define a complex structural epitope on DIII of DENV-1 that can be recognized by protective antibodies with therapeutic potential.


Zdroje

1. BurkeDS

MonathTP

2001 Flaviviruses.

KnipeDM

HowleyPM

Fields Virology. Fourth Edition ed Philadelphia Lippincott Williams &Wilkins 1043 1125

2. Rico-HesseR

1990 Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 174 479 493

3. HolmesEC

TwiddySS

2003 The origin, emergence and evolutionary genetics of dengue virus. Infect Genet Evol 3 19 28

4. HalsteadSB

1988 Pathogenesis of dengue: challenges to molecular biology. Science 239 476 481

5. MonathTP

1994 Dengue: the risk to developed and developing countries. Proc Natl Acad Sci U S A 91 2395 2400

6. ChambersTJ

HahnCS

GallerR

RiceCM

1990 Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44 649 688

7. KuhnRJ

ZhangW

RossmannMG

PletnevSV

CorverJ

2002 Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108 717 725

8. ZhangY

CorverJ

ChipmanPR

ZhangW

PletnevSV

2003 Structures of immature flavivirus particles. Embo J 22 2604 2613

9. ModisY

OgataS

ClementsD

HarrisonSC

2003 A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100 6986 6991

10. ModisY

OgataS

ClementsD

HarrisonSC

2005 Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79 1223 1231

11. NayakV

DessauM

KuceraK

AnthonyK

LedizetM

2009 Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. J Virol 83 4338 4344

12. MondotteJA

LozachPY

AmaraA

GamarnikAV

2007 Essential Role of Dengue Virus Envelope Protein N Glycosylation at Asparagine-67 during Viral Propagation. J Virol 81 7136 7148

13. PokidyshevaE

ZhangY

BattistiAJ

Bator-KellyCM

ChipmanPR

2006 Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124 485 493

14. TassaneetrithepB

BurgessT

Granelli-PipernoA

TrumpfhellerC

FinkeJ

2003 DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197 823 829

15. Navarro-SanchezE

AltmeyerR

AmaraA

SchwartzO

FieschiF

2003 Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 4 723 728

16. ReyFA

HeinzFX

MandlC

KunzC

HarrisonSC

1995 The envelope glycoprotein from tick-borne encephalitis virus at 2 Angstrom resolution. Nature 375 291 298

17. BhardwajS

HolbrookM

ShopeRE

BarrettAD

WatowichSJ

2001 Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol 75 4002 4007

18. VolkDE

BeasleyDW

KallickDA

HolbrookMR

BarrettAD

2004 Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. J Biol Chem 279 38755 38761

19. YuS

WuuA

BasuR

HolbrookMR

BarrettAD

2004 Solution structure and structural dynamics of envelope protein domain III of mosquito- and tick-borne flaviviruses. Biochemistry 43 9168 9176

20. LiL

LokSM

YuIM

ZhangY

KuhnRJ

2008 The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319 1830 1834

21. YuIM

ZhangW

HoldawayHA

LiL

KostyuchenkoVA

2008 Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319 1834 1837

22. PiersonTC

FremontDH

KuhnRJ

DiamondMS

2008 Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4 229 238

23. RoehrigJT

MathewsJH

TrentDW

1983 Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies. Virology 128 118 126

24. RoehrigJT

StaudingerLA

HuntAR

MathewsJH

BlairCD

2001 Antibody prophylaxis and therapy for flaviviral encephalitis infections. Ann NY Acad Sci 286 297

25. LokSM

KostyuchenkoV

NybakkenGE

HoldawayHA

BattistiAJ

2008 Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15 312 317

26. Sukupolvi-PettyS

PurthaWE

AustinSK

OliphantT

NybakkenG

2007 Type- and Sub-Complex-Specific Neutralizing Antibodies Against Domain III of Dengue Virus Type-2 Envelope Protein Recognize Adjacent Epitopes. J Virol 81 12816 12826

27. GromowskiGD

BarrettND

BarrettAD

2008 Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82 8828 8837

28. DiamondMS

SitatiE

FriendL

ShresthaB

HiggsS

2003 Induced IgM protects against lethal West Nile Virus infection. J Exp Med 198 1 11

29. OliphantT

EngleM

NybakkenG

DoaneC

JohnsonS

2005 Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nature Medicine 11 522 530

30. BrandrissMW

SchlesingerJJ

WalshEE

BriselliM

1986 Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol 67 229 234

31. GouldEA

BuckleyA

BarrettAD

CammackN

1986 Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol 67 ( Pt 3) 591 595

32. BeasleyDW

BarrettAD

2002 Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 76 13097 13100

33. CrillWD

RoehrigJT

2001 Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75 7769 7773

34. RoehrigJT

BolinRA

KellyRG

1998 Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246 317 328

35. SanchezMD

PiersonTC

McAllisterD

HannaSL

PufferBA

2005 Characterization of neutralizing antibodies to West Nile virus. Virology 336 70 82

36. CeciliaD

GouldEA

1991 Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology 181 70 77

37. SeifSA

MoritaK

MatsuoS

HasebeF

IgarashiA

1995 Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system. Vaccine 13 1515 1521

38. WuSC

LianWC

HsuLC

LiauMY

1997 Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence. Virus Res 51 173 181

39. SchlesingerJJ

ChapmanS

NestorowiczA

RiceCM

GinocchioTE

1996 Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain. J Gen Virol 77 ( Pt 6) 1277 1285

40. LinB

ParrishCR

MurrayJM

WrightPJ

1994 Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 202 885 890

41. GromowskiGD

BarrettAD

2007 Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366 349 360

42. LaiCJ

GoncalvezAP

MenR

WernlyC

DonauO

2007 Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J Virol 81 12766 12774

43. DiamondMS

2009 Progress on the development of therapeutics against West Nile virus. Antiviral Res 83 214 227

44. SimantiniE

BanerjeeK

1995 Epitope mapping of dengue 1 virus E glycoprotein using monoclonal antibodies. Arch Virol 140 1257 1273

45. ChenYC

HuangHN

LinCT

ChenYF

KingCC

2007 Generation and characterization of monoclonal antibodies against dengue virus type 1 for epitope mapping and serological detection by epitope-based peptide antigens. Clin Vaccine Immunol 14 404 411

46. BeasleyDW

AaskovJG

2001 Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies. Virology 279 447 458

47. GoncalvezAP

EscalanteAA

PujolFH

LudertJE

TovarD

2002 Diversity and evolution of the envelope gene of dengue virus type 1. Virology 303 110 119

48. VogtMR

MoeskerB

GoudsmitJ

JongeneelenM

AustinSK

2009 Human Monoclonal Antibodies Induced by Natural Infection Against West Nile Virus Neutralize at a Post-Attachment Step. J Virol 83 6494 6507

49. MorreyJD

SiddharthanV

OlsenAL

RoperGY

WangH

2006 Humanized monoclonal antibody against West Nile virus E protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis 194 1300 1308

50. MorreyJD

SiddharthanV

OlsenAL

WangH

JulanderJG

2007 Defining limits of humanized neutralizing monoclonal antibody treatment for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother 51 2396 2402

51. ZhangW

ChipmanPR

CorverJ

JohnsonPR

ZhangY

2003 Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol 10 907 912

52. OliphantT

NybakkenGE

EngleM

XuQ

NelsonCA

2006 Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80 12149 12159

53. GouldLH

SuiJ

FoellmerH

OliphantT

WangT

2005 Protective and therapeutic capacity of human single chain Fv-Fc fusion proteins against West Nile virus. J Virol 79 14606 14613

54. ThrosbyM

GeuijenC

GoudsmitJ

BakkerAQ

KorimbocusJ

2006 Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 80 6982 6992

55. SultanaH

FoellmerHG

NeelakantaG

OliphantT

EngleM

2009 Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J Immunol 183 650 660

56. JohnsonAJ

RoehrigJT

1999 New mouse model for dengue virus vaccine testing. J Virol 73 783 786

57. GoncalvezAP

ChienCH

TubthongK

GorshkovaI

RollC

2008 Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol 82 7009 7021

58. GoncalvezAP

PurcellRH

LaiCJ

2004 Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J Virol 78 12919 12928

59. LeitmeyerKC

VaughnDW

WattsDM

SalasR

VillalobosI

1999 Dengue virus structural differences that correlate with pathogenesis. J Virol 73 4738 4747

60. Rico-HesseR

2007 Dengue virus evolution and virulence models. Clin Infect Dis 44 1462 1466

61. Rico-HesseR

HarrisonLM

SalasRA

TovarD

NisalakA

1997 Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 230 244 251

62. ArmstrongPM

Rico-HesseR

2003 Efficiency of dengue serotype 2 virus strains to infect and disseminate in Aedes aegypti. Am J Trop Med Hyg 68 539 544

63. Rico-HesseR

2003 Microevolution and virulence of dengue viruses. Adv Virus Res 59 315 341

64. LisovaO

HardyF

PetitV

BedouelleH

2007 Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. J Gen Virol 88 2387 2397

65. ThullierP

DemangelC

BedouelleH

MegretF

JouanA

2001 Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 82 1885 1892

66. RajamanonmaniR

NkenfouC

ClancyP

YauYH

ShochatSG

2009 On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol 90 799 809

67. MatsuiK

GromowskiGD

LiL

SchuhAJ

LeeJC

2009 Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. Virology 384 16 20

68. CrillWD

ChangGJ

2004 Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78 13975 13986

69. CrillWD

TrainorNB

ChangGJ

2007 A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles. J Gen Virol 88 1169 1174

70. ChenZ

LiuLM

GaoN

XuXF

ZhangJL

2009 Passive protection assay of monoclonal antibodies against dengue virus in suckling mice. Curr Microbiol 58 326 331

71. KaufmanBM

SummersPL

DuboisDR

EckelsKH

1987 Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 36 427 434

72. EngleM

DiamondMS

2003 Antibody prophylaxis and therapy against West Nile Virus infection in wild type and immunodeficient mice. J Virol 77 12941 12949

73. Ben-NathanD

Gershoni-YahalomO

SaminaI

KhinichY

NurI

2009 Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis 9 18

74. Ben-NathanD

LustigS

TamG

RobinzonS

SegalS

2003 Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating west nile virus infection in mice. J Infect Dis 188 5 12

75. ZhangMJ

WangMJ

JiangSZ

MaWY

1989 Passive protection of mice, goats, and monkeys against Japanese encephalitis with monoclonal antibodies. J Med Virol 29 133 138

76. Kimura-KurodaJ

YasuiK

1988 Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 141 3606 3610

77. KreilTR

EiblMM

1997 Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol 71 2921 2927

78. VaughnDW

GreenS

KalayanaroojS

InnisBL

NimmannityaS

2000 Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity. J Infect Dis 181 2 9

79. XiaoSY

GuzmanH

ZhangH

Travassos da RosaAP

TeshRB

2001 West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis 7 714 721

80. DiamondMS

ShresthaB

MarriA

MahanD

EngleM

2003 B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 77 2578 2586

81. PiersonTC

XuQ

NelsonS

OliphantT

NybakkenGE

2007 The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host and Microbe 1 135 145

82. KlassePJ

2007 Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology 369 245 262

83. GollinsS

PorterfieldJ

1984 Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody and viral fate. J Gen Virol 65 1261 1272

84. HalsteadSB

1994 Antibody-dependent enhancement of infection: a mechanism for indirect virus entry into cells. Cellular Receptors for Animal Viruses Cold Spring Harbor Cold Spring Harbor Laboratory Press 493 516

85. HalsteadSB

1979 In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140 527 533

86. GoncalvezAP

EngleRE

St ClaireM

PurcellRH

LaiCJ

2007 Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104 9422 9427

87. MehlhopE

Ansarah-SobrinhoC

JohnsonS

EngleM

FremontDH

2007 Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host and Microbe 2 417 426

88. BalsitisSJ

WilliamsKL

LachicaR

FloresD

KyleJL

2010 Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6 e1000790 doi:10.1371/journal.ppat.1000790

89. HiramatsuK

TadanoM

MenR

LaiCJ

1996 Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology 224 437 445

90. SerafinIL

AaskovJG

2001 Identification of epitopes on the envelope (E) protein of dengue 2 and dengue 3 viruses using monoclonal antibodies. Arch Virol 146 2469 2479

91. MegretF

HugnotJP

FalconarA

GentryMK

MorensDM

1992 Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 187 480 491

92. TrirawatanapongT

ChandranB

PutnakR

PadmanabhanR

1992 Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene 116 139 150

93. NybakkenG

OliphantT

JohnsonS

BurkeS

DiamondMS

2005 Structural basis for neutralization of a therapeutic antibody against West Nile virus. Nature 437 764 769

94. CherrierMV

KaufmannB

NybakkenGE

LokSM

WarrenJT

2009 Structural basis for the preferential binding of immature flaviviruses by a fusion-loop specific antibody. EMBO 28 3269 3276

95. OliphantT

NybakkenGE

AustinSK

XuQ

BramsonJ

2007 The Induction of Epitope-Specific Neutralizing Antibodies against West Nile virus. J Virol 81 11828 11839

96. WahalaWM

KrausAA

HaymoreLB

Accavitti-LoperMA

de SilvaAM

2009 Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392 103 113

97. CrillWD

HughesHR

DeloreyMJ

ChangGJ

2009 Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS ONE 4 e4991 doi:10.1371/journal.pone.0004991

98. HermidaL

BernardoL

MartinJ

AlvarezM

PradoI

2006 A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24 3165 3171

99. ChuJH

ChiangCC

NgML

2007 Immunization of Flavivirus West Nile Recombinant Envelope Domain III Protein Induced Specific Immune Response and Protection against West Nile Virus Infection. J Immunol 178 2699 2705

100. ChenS

YuM

JiangT

DengY

QinC

2007 Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol 26 361 367

101. ValdesI

BernardoL

GilL

PavonA

LazoL

2009 A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 394 249 258

102. HarlowE

LaneD

1988 Antibodies, A laboratory manual Cold Spring Harbor Cold Spring Harbor Laboratory 714

103. MinorW

CymborowskiM

OtwinowskiZ

ChruszczM

2006 HKL-3000: the integration of data reduction and structure solution–from diffraction images to an initial model in minutes. Acta Crystallogr D Biol Crystallogr 62 859 866

104. McCoyAJ

Grosse-KunstleveRW

AdamsPD

WinnMD

StoroniLC

2007 Phaser crystallographic software. J Appl Crystallogr 40 658 674

105. JonesEY

WalkerNP

StuartDI

1991 Methodology employed for the structure determination of tumour necrosis factor, a case of high non-crystallographic symmetry. Acta Crystallogr A 47 ( Pt 6) 753 770

106. WinnMD

MurshudovGN

PapizMZ

2003 Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol 374 300 321

107. ShindyalovIN

BournePE

1998 Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Eng 11 739 747

108. BoderET

WittrupKD

1997 Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15 553 557

109. BoderET

WittrupKD

1998 Optimal screening of surface-displayed polypeptide libraries. Biotechnol Prog 14 55 62

110. PottertonL

McNicholasS

KrissinelE

GruberJ

CowtanK

2004 Developments in the CCP4 molecular-graphics project. Acta Crystallogr D Biol Crystallogr 60 2288 2294

111. BartonGJ

1993 ALSCRIPT: a tool to format multiple sequence alignments. Protein Eng 6 37 40

112. KabschW

SanderC

1983 Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22 2577 2637

Štítky
Hygiena a epidemiológia Infekčné lekárstvo Laboratórium

Článok vyšiel v časopise

PLOS Pathogens


2010 Číslo 4
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Eozinofilní granulomatóza s polyangiitidou
nový kurz
Autori: doc. MUDr. Martina Doubková, Ph.D.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa